Scheidig A J, Hynes T R, Pelletier L A, Wells J A, Kossiakoff A A
Protein Engineering Department, Genentech, Inc., South San Francisco, California 94080, USA.
Protein Sci. 1997 Sep;6(9):1806-24. doi: 10.1002/pro.5560060902.
The crystal structures of the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) complexed to bovine chymotrypsin (C-APPI) and trypsin (T-APPI) and basic pancreatic trypsin inhibitor (BPTI) bound to chymotrypsin (C-BPTI) have been solved and analyzed at 2.1 A, 1.8 A, and 2.6 A resolution, respectively. APPI and BPTI belong to the Kunitz family of inhibitors, which is characterized by a distinctive tertiary fold with three conserved disulfide bonds. At the specificity-determining site of these inhibitors (P1), residue 15(I)4 is an arginine in APPI and a lysine in BPTI, residue types that are counter to the chymotryptic hydrophobic specificity. In the chymotrypsin complexes, the Arg and Lys P1 side chains of the inhibitors adopt conformations that bend away from the bottom of the binding pocket to interact productively with elements of the binding pocket other than those observed for specificity-matched P1 side chains. The stereochemistry of the nucleophilic hydroxyl of Ser 195 in chymotrypsin relative to the scissile P1 bond of the inhibitors is identical to that observed for these groups in the trypsin-APPI complex, where Arg 15(I) is an optimal side chain for tryptic specificity. To further evaluate the diversity of sequences that can be accommodated by one of these inhibitors, APPI, we used phage display to randomly mutate residues 11, 13, 15, 17, and 19, which are major binding determinants. Inhibitors variants were selected that bound to either trypsin or chymotrypsin. As expected, trypsin specificity was principally directed by having a basic side chain at P1 (position 15); however, the P1 residues that were selected for chymotrypsin binding were His and Asn, rather than the expected large hydrophobic types. This can be rationalized by modeling these hydrophilic side chains to have similar H-bonding interactions to those observed in the structures of the described complexes. The specificity, or lack thereof, for the other individual subsites is discussed in the context of the "allowed" residues determined from a phage display mutagenesis selection experiment.
已分别以2.1埃、1.8埃和2.6埃的分辨率解析并分析了与牛胰凝乳蛋白酶(C - APPI)和胰蛋白酶(T - APPI)复合的阿尔茨海默病淀粉样β蛋白前体(APPI)抑制结构域以及与胰凝乳蛋白酶(C - BPTI)结合的碱性胰蛋白酶抑制剂(BPTI)的晶体结构。APPI和BPTI属于Kunitz抑制剂家族,其特征是具有独特的三级结构,带有三个保守的二硫键。在这些抑制剂的特异性决定位点(P1),APPI中的第15(I)4位残基是精氨酸,BPTI中的是赖氨酸,这些残基类型与胰凝乳蛋白酶的疏水特异性相反。在胰凝乳蛋白酶复合物中,抑制剂的精氨酸和赖氨酸P1侧链采取的构象是从结合口袋底部弯曲开,以便与结合口袋中除特异性匹配的P1侧链所观察到的元素之外的其他元素进行有效相互作用。胰凝乳蛋白酶中Ser 195的亲核羟基相对于抑制剂的可裂解P1键的立体化学与在胰蛋白酶 - APPI复合物中这些基团所观察到的相同,其中Arg 15(I)是胰蛋白酶特异性的最佳侧链。为了进一步评估这些抑制剂之一APPI能够容纳的序列多样性,我们使用噬菌体展示对主要结合决定因素的第11、13、15、17和19位残基进行随机诱变。选择了与胰蛋白酶或胰凝乳蛋白酶结合的抑制剂变体。正如预期的那样,胰蛋白酶特异性主要由P1(第15位)处的碱性侧链决定;然而,为与胰凝乳蛋白酶结合而选择的P1残基是组氨酸和天冬酰胺,而不是预期的大的疏水类型。通过对这些亲水性侧链进行建模,使其具有与所述复合物结构中观察到的类似氢键相互作用,可以对此进行合理解释。在从噬菌体展示诱变选择实验确定的“允许”残基的背景下,讨论了对其他各个亚位点的特异性或缺乏特异性的情况。